Archive · 21 Aug 2025
Novo Nordisk Faces Layoffs Amid Wegovy Sales Slowdown
Novo Nordisk, the company behind the weight-loss drug Wegovy, is slowing down.
They hired lots of people quickly when Wegovy was very popular, but now sales are not growing as fast.
The company is looking for ways to cut costs, like possibly firing some employees.
They've already stopped hiring for some jobs.
Experts think the sales team might be reduced, especially those selling an older medicine.
The stock market has also shown concern, as the company's value has fallen.
Novo Nordisk is facing potential layoffs after rapid expansion due to slowing sales of Wegovy.
The company's workforce nearly doubled from 2019 to 2023 to meet Wegovy demand.
CEO Maziar Mike Doustdar announced a global hiring freeze for non-critical roles.
Analysts anticipate layoffs in the sales division, especially for Rybelsus, a diabetes treatment.
Novo Nordisk's gross margin has been squeezed, and the stock market value has decreased.
- Who
- Novo Nordisk, a pharmaceutical company, and its employees.
- What
- Novo Nordisk is considering layoffs due to slowing sales of Wegovy and cost pressures.
- When
- The hiring freeze was implemented in August 2024.
- Where
- The impact is global, with potential layoffs in the US and Denmark.
- Why
- Slowing sales and increased competition are forcing cost-cutting measures.
Concerns and Actions
Market Performance
Cost Management
Concerns and Actions
The company is facing cost pressures and has seen its gross margin squeezed.
Market Performance
The company is taking steps to reduce costs through a hiring freeze and potential layoffs.
- Company
- Novo Nordisk
- Drug in Focus
- Wegovy
- Workforce Increase
- From ~43,260 in 2019 to ~77,350 by 2023
- Hiring Freeze
- Implemented for non-critical roles
- CEO
- Maziar Mike Doustdar
- Layoff Anticipation
- Sales division
- Market Capitalization Decrease
- $490 billion
